Predict your next investment

Holding Company
HEALTHCARE | Pharmaceuticals / Drugs
otsuka.com

See what CB Insights has to offer

Investments

42

Portfolio Exits

2

Partners & Customers

5

About Otsuka Holdings

Otsuka Holdings (TYO: 4578) is the holding company for a number of pharmaceutical companies, including Otsuka Pharmaceutical, Otsuka Pharmaceutical Factory, Taiho Pharmaceutical, Otsuka Warehouse, Otsuka Chemical, and Otsuka Medical Devices.

Otsuka Holdings Headquarter Location

2-9 Kanda-Tsukasamachi Chiyoda-ku

Tokyo, 101-0048,

Japan

Predict your next investment

The CB Insights tech market intelligence platform analyzes millions of data points on venture capital, startups, patents , partnerships and news mentions to help you see tomorrow's opportunities, today.

Otsuka Holdings Web Traffic

Rank
Page Views per User (PVPU)
Page Views per Million (PVPM)
Reach per Million (RPM)
CBI Logo

Otsuka Holdings Rank

Research containing Otsuka Holdings

Get data-driven expert analysis from the CB Insights Intelligence Unit.

CB Insights Intelligence Analysts have mentioned Otsuka Holdings in 1 CB Insights research brief, most recently on Jun 30, 2021.

Latest Otsuka Holdings News

Otsuka files for EMA approval of vadadustat

Nov 1, 2021

Shares of Otsuka Holdings were up 2.8% at 4,620 yen today, as the Japanese drugmaker announced that its… To continue reading The Pharma Letter please login ,   subscribe  or  claim a 7 day free trial subscription  and access exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space. Or, if you're only interested in reading the content about a specific topic (M&A, coronavirus/COVID-19, pricing, reimbursement and access, outsourcing, CRO and CMO, and regulation), then you can take our £10 per month channel subscription offer, which gives you access to all our news articles and in-depth content on this subject.

Otsuka Holdings Investments

42 Investments

Otsuka Holdings has made 42 investments. Their latest investment was in Renascience as part of their Series A on March 3, 2019.

CBI Logo

Otsuka Holdings Investments Activity

investments chart

Date

Round

Company

Amount

New?

Co-Investors

Sources

3/11/2019

Series A

Renascience

Yes

1

9/25/2018

Series B - II

StartUp Health

$31M

Yes

1

12/25/2017

Series C

Megakaryon

$33.37M

Yes

6

4/10/2015

Series D

Subscribe to see more

$99M

Subscribe to see more

10

5/1/2013

Series F - II

Subscribe to see more

$99M

Subscribe to see more

10

Date

3/11/2019

9/25/2018

12/25/2017

4/10/2015

5/1/2013

Round

Series A

Series B - II

Series C

Series D

Series F - II

Company

Renascience

StartUp Health

Megakaryon

Subscribe to see more

Subscribe to see more

Amount

$31M

$33.37M

$99M

$99M

New?

Yes

Yes

Yes

Subscribe to see more

Subscribe to see more

Co-Investors

Sources

1

1

6

10

10

Otsuka Holdings Portfolio Exits

2 Portfolio Exits

Otsuka Holdings has 2 portfolio exits. Their latest portfolio exit was SomaLogic on March 29, 2021.

Date

Exit

Companies

Valuation
Valuations are submitted by companies, mined from state filings or news, provided by VentureSource, or based on a comparables valuation model.

Acquirer

Sources

3/29/2021

Acq - Pending

$991

3

00/00/0000

Subscribe to see more

Subscribe to see more

Subscribe to see more

10

Date

3/29/2021

00/00/0000

Exit

Acq - Pending

Subscribe to see more

Companies

Subscribe to see more

Valuation

$991

Acquirer

Subscribe to see more

Sources

3

10

Otsuka Holdings Acquisitions

7 Acquisitions

Otsuka Holdings acquired 7 companies. Their latest acquisition was Visterra on July 11, 2018.

Date

Investment Stage

Companies

Valuation
Valuations are submitted by companies, mined from state filings or news, provided by VentureSource, or based on a comparables valuation model.

Total Funding

Note

Sources

7/11/2018

Series C

$991

$124.99M

Acquired

4

7/10/2018

Debt

Subscribe to see more

$99M

Subscribe to see more

10

1/25/2018

Corporate Minority

Subscribe to see more

$99M

Subscribe to see more

10

7/27/2017

Subscribe to see more

$991

$99M

Subscribe to see more

10

3/2/2017

Debt

Subscribe to see more

$991

$99M

Subscribe to see more

10

Date

7/11/2018

7/10/2018

1/25/2018

7/27/2017

3/2/2017

Investment Stage

Series C

Debt

Corporate Minority

Debt

Companies

Subscribe to see more

Subscribe to see more

Subscribe to see more

Subscribe to see more

Valuation

$991

$991

$991

Total Funding

$124.99M

$99M

$99M

$99M

$99M

Note

Acquired

Subscribe to see more

Subscribe to see more

Subscribe to see more

Subscribe to see more

Sources

4

10

10

10

10

Otsuka Holdings Partners & Customers

5 Partners and customers

Otsuka Holdings has 5 strategic partners and customers. Otsuka Holdings recently partnered with Sumitomo Dainippon Pharma on September 9, 2021.

Date

Type

Business Partner

Country

News Snippet

Sources

9/30/2021

Licensor

Sumitomo Dainippon Pharma

Japan

Otsuka Pharmaceutical Co., Ltd. Otsuka Pharmaceutical Co., Ltd. and License Agreement for Four Psychiatry and Neurology Compounds. Sumitomo Dainippon Pharma and Otsuka Announce a Worldwide Collaborationand License Agreement for Four Psychiatry and Neurology Compounds|News Releases

Sumitomo Dainippon Pharma -LRB- Head Office : Osaka , Japan ; Representative Director , President and CEO : Hiroshi Nomura ; Securities Code : 4506 , First Section of TSE -RRB- , its U.S.-based subsidiary Sunovion Pharmaceuticals Inc. and Otsuka Pharmaceutical Co. , Ltd. -LRB- Head Office : Tokyo , Japan ; Representative Director , President and CEO : Makoto Inoue -RRB- announce today that we have executed a collaboration and license agreement for worldwide joint development and commercialization of the following four novel candidate compounds -LRB- hereinafter referred to as the `` four compounds '' -RRB- currently under development in psychiatry and neurology area by Sumitomo Dainippon Pharma and Sunovion Pharmaceuticals Inc. .

1

2/24/2021

Licensor

Subscribe to see more

Subscribe to see more

Subscribe to see more

10

12/17/2020

Licensor

Subscribe to see more

Subscribe to see more

Subscribe to see more

10

5/21/2019

Partner

Subscribe to see more

Subscribe to see more

Subscribe to see more

10

5/16/2016

Partner

Subscribe to see more

Subscribe to see more

Subscribe to see more

10

Date

9/30/2021

2/24/2021

12/17/2020

5/21/2019

5/16/2016

Type

Licensor

Licensor

Licensor

Partner

Partner

Business Partner

Sumitomo Dainippon Pharma

Country

Japan

Subscribe to see more

Subscribe to see more

Subscribe to see more

Subscribe to see more

News Snippet

Otsuka Pharmaceutical Co., Ltd. Otsuka Pharmaceutical Co., Ltd. and License Agreement for Four Psychiatry and Neurology Compounds. Sumitomo Dainippon Pharma and Otsuka Announce a Worldwide Collaborationand License Agreement for Four Psychiatry and Neurology Compounds|News Releases

Sumitomo Dainippon Pharma -LRB- Head Office : Osaka , Japan ; Representative Director , President and CEO : Hiroshi Nomura ; Securities Code : 4506 , First Section of TSE -RRB- , its U.S.-based subsidiary Sunovion Pharmaceuticals Inc. and Otsuka Pharmaceutical Co. , Ltd. -LRB- Head Office : Tokyo , Japan ; Representative Director , President and CEO : Makoto Inoue -RRB- announce today that we have executed a collaboration and license agreement for worldwide joint development and commercialization of the following four novel candidate compounds -LRB- hereinafter referred to as the `` four compounds '' -RRB- currently under development in psychiatry and neurology area by Sumitomo Dainippon Pharma and Sunovion Pharmaceuticals Inc. .

Subscribe to see more

Subscribe to see more

Subscribe to see more

Subscribe to see more

Subscribe to see more

Subscribe to see more

Subscribe to see more

Subscribe to see more

Sources

1

10

10

10

10

CB Insights uses Cookies

CBI websites generally use certain cookies to enable better interactions with our sites and services. Use of these cookies, which may be stored on your device, permits us to improve and customize your experience. You can read more about your cookie choices at our privacy policy here. By continuing to use this site you are consenting to these choices.